Trends nds i in Personaliz nalized ed Medicine icine Scot - - PowerPoint PPT Presentation
Trends nds i in Personaliz nalized ed Medicine icine Scot cott Jenki Jenkins, Ph. h. D. Vice e President ident Dell l Healt lthcar hcare e & Life Sciences nces Time M me Magazine ine Januar January 18, 18, 2010 2010
Scot cott Jenki Jenkins, Ph.
Vice e President ident Dell l Healt lthcar hcare e & Life Sciences nces
DELL CONFIDENTIAL
Independent (600K)
Sell to
10,000+ hospitals, 750,000+ physicians – Employed (150K) Independent(300 Affiliated, 300 Unaffiliated)
Hospita l 1 Hospita l 2 Hospita l 5 Hospita l 4 Hospita l 3
Affiliated (300K)
Hospital Hospital, then Doc
Employed (150k)
Doc
4
Confidential
Governance a Governance and nd Project Management Office Project Management Office Design, D Design, Deployment, eployment, Hosting and Helpdesk Hosting and Helpdesk Support Support
DELL CONFIDENTIAL
Metcalfe's law characterizes many of the network effects of communication
technologies and networks such as the
Internet, social networking, and the World Wide Web. It is related to the fact that the number
number of nodes (n) can be expressed mathematically as the triangular number
n(n − 1)/2, which is proportional to n2
asymptotically.
DELL CONFIDENTIAL
10 yrs 15 yrs 5 yrs
DELL CONFIDENTIAL
Patient scenario in the future
quality of life
span
Source: Science, Vol. 207, 17 March 2000
Genotype recorded Secure database
+
Personalized immunization Screening schedule Preventive measures
+
Life Screening based on biomolecular profiling Refined treatment Drugs Developed to target particular disease subtypes on particular genetic background
Baby Hospital Adult
Physician’s office
BioBank
DELL CONFIDENTIAL
DELL CONFIDENTIAL
GCCCACCTC GCCCGCCTC
Diagnostics/Biomarkers Drug Metabolism
11 Data from IMS HEALTH: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Global_Top_15_Products.pdf
Note: Lipitor loses patent exclusivity in 2011 – Generic Drugs will be available
DELL CONFIDENTIAL
Answer: The HIPAA Privacy Rule recognizes that a deceased individual’s protected health information may be relevant to a family member’s health care. The Rule provides two ways for a surviving family member to obtain the protected health information of a deceased relative. First, disclosures of protected health information for treatment purposes—even the treatment of another individual—do not require an authorization; thus, a covered entity may disclose a decedent’s protected health information, w ithout authorization, to the health care provider w ho is treating the surviving relative. How can family members of a deceased individual obtain the deceased individual's protected health information that is relevant to their ow n health care? Second
, a covered ed entity mu must treat a deceas ased ed indiv ividual’ idual’s legall gally author horiz ized ed execut utor
nistrator
, or a person
erw is ise e legally aut authorized to
act on
he behal behalf of
he decea deceased indi ndividual or
his estate, e, as a personal
esent entativ ive e w ith h respect ect to protect ected ed healt lth h infor
mation ion relevant ant to such ch repres esent entation. ion. Theref efor
e, if it is w ithin in the scope e of such ch personal
esent entativ ive’ e’s aut authority unde under ot
her law, the he Rul ule e per permits the he per personal repr presentative to obtain ain the informa mation ion or provide de the appropr
iate e author
ization ion for its disclos losur ure. e.
DELL CONFIDENTIAL
Source: NY Time, Sep 16, 2007
Personalized Medicine - Biomarkers
Diagnostic Monitoring
Preventative Measures
DELL CONFIDENTIAL
Novartis CEO Daniel Vasella
Health Blog WSJ's blog on health and the business of health
JANUARY 3, 2008, 9:23 AM ET
DELL CONFIDENTIAL
Basic Medicine
Personalized Medicine in Action
(was included as an after thought)
(Plasminogen activator inhibitor-1)
counteract natural mechanism
DELL CONFIDENTIAL